Relation-Aware Shared Representation Learning for Cancer Prognosis Analysis With Auxiliary Clinical Variables and
IEEE Transactions on Medical Imaging
|August 30, 2021
Summary
This study introduces a novel relation-aware method for cancer prognosis, effectively integrating multi-modality data and clinical information. The approach enhances predictive accuracy by learning shared representations and handling incomplete datasets for robust cancer outcome prediction.
Area of Science:
- Computational biology
- Bioinformatics
- Medical data analysis
Background:
- Multi-modality data integration (histopathology, genomics) advances cancer prognosis.
- Challenges include exploring inter-modality relations and handling incomplete data.
- Existing methods often overlook valuable clinical variables like grade and stage.
Purpose of the Study:
- To propose a relation-aware shared representation learning method for cancer prognosis.
- To effectively utilize clinical information and incomplete multi-modality data.
- To develop a robust prognostic model by addressing key challenges in multi-modality analysis.
Main Methods:
- Learned a multi-modal shared space using dual mapping for prognostic modeling.
- Employed relational regularizers to explore feature-label and feature-feature relationships.
- Incorporated auxiliary clinical attributes and used a partial mapping strategy for incomplete data.
Main Results:
- The proposed method demonstrated superior performance on three public datasets from The Cancer Genome Atlas (TCGA).
- Relational regularizers induced discriminatory representations and enhanced sparsity.
- Integration of clinical variables and handling of incomplete data improved model accuracy and robustness.
Conclusions:
- The developed relation-aware method offers a powerful approach for cancer prognosis using multi-modality data.
- The strategy effectively addresses challenges of inter-modality relations and data incompleteness.
- This work provides a foundation for more accurate and reliable cancer outcome prediction models.
Related Concept Videos
Cancer Survival Analysis
481
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
481
Combination Therapies and Personalized Medicine
5.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Tumor Progression
6.7K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.7K
mTOR Signaling and Cancer Progression
4.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.0K
Targeted Cancer Therapies
8.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.0K


